Jun 09, 2020 / 05:40PM GMT
Malgorzata Maria Kaczor - William Blair & Company L.L.C., Research Division - Research Analyst
Hey, good morning, everyone. Thanks for joining us. My name is Margaret Kaczor, and I am the research analyst here at William Blair & Company who covers DexCom.
Now before we begin, I am required to inform you that I personally own shares of DexCom. But beyond that, you can obtain a complete list of research disclosures or potential conflicts of interest at williamblair.com.
I'll do a short introduction then we'll kind of drive over to Q&A. But DexCom has been one of the top-performing stocks on our coverage universe over the last -- now 3 years probably. And despite the years of strong growth, sales continue to accelerate in spite of competition, pricing and tough comps. The impact of the pandemic is a little uncertain. We'll talk about that. But ultimately, as we look at the stock, the story from here is, where does diabetes management go over the next 3 years? Over the next 5 years? How important is innovation and access and data? And from our perspective, DexCom has been
DexCom Inc at William Blair Growth Stock Conference Transcript
Jun 09, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers